Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation

Joseph Bubalo, Ganesh Cherala, Jeannine S. McCune, Myrna Y. Munar, Sunny Tse, Richard Maziarz

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Aprepitant, a neurokinin antagonist, is an effective antiemetic agent in chemotherapy for delayed nausea and vomiting. The study objective was to evaluate the pharmacokinetics of aprepitant and concurrent cyclophosphamide (CY), often a component of hematopoietic stem cell transplant (HSCT) conditioning regimen, in cancer patients undergoing HSCT. Forty subjects were randomized to either aprepitant or placebo in addition to standard antiemetics. Aprepitant or placebo was started 1 hour before the first chemotherapy or radiation dose for HSCT conditioning and administered daily until 4 days after infusion of the hematopoietic cell graft (for a total of 10-12 days). Serial blood samples were collected for aprepitant and CY plus 2 important CY metabolites. The results indicate that aprepitant is well absorbed and does not auto-induce its metabolism. No significant drug interaction was observed with CY or its metabolites. A significant portion of the patients had subtherapeutic aprepitant concentrations; however, chemotherapy-induced nausea and vomiting were effectively managed. No dosage adjustment was necessary, and administration of aprepitant in HSCT at the prescribed dosage of 125 mg orally on day 1 and 80 mg orally on each consecutive day through day +4 after HSCT was well tolerated with no significant changes in CY pharmacokinetic parameters.

Original languageEnglish (US)
Pages (from-to)586-594
Number of pages9
JournalJournal of Clinical Pharmacology
Volume52
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

aprepitant
Hematopoietic Stem Cell Transplantation
Cyclophosphamide
Pharmacokinetics
Hematopoietic Stem Cells
Transplants
Neoplasms
Antiemetics
Drug Therapy
Nausea
Vomiting
Placebos
Drug Interactions

Keywords

  • aprepitant
  • azole antifungals
  • cyclophosphamide
  • CYP450
  • Hematopoietic cell transplant
  • myeloablative regimen
  • pharmacokinetics
  • sinusoidal obstruction syndrome

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation. / Bubalo, Joseph; Cherala, Ganesh; McCune, Jeannine S.; Munar, Myrna Y.; Tse, Sunny; Maziarz, Richard.

In: Journal of Clinical Pharmacology, Vol. 52, No. 4, 04.2012, p. 586-594.

Research output: Contribution to journalArticle

@article{04c5268610094a45bc007677cf911acf,
title = "Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation",
abstract = "Aprepitant, a neurokinin antagonist, is an effective antiemetic agent in chemotherapy for delayed nausea and vomiting. The study objective was to evaluate the pharmacokinetics of aprepitant and concurrent cyclophosphamide (CY), often a component of hematopoietic stem cell transplant (HSCT) conditioning regimen, in cancer patients undergoing HSCT. Forty subjects were randomized to either aprepitant or placebo in addition to standard antiemetics. Aprepitant or placebo was started 1 hour before the first chemotherapy or radiation dose for HSCT conditioning and administered daily until 4 days after infusion of the hematopoietic cell graft (for a total of 10-12 days). Serial blood samples were collected for aprepitant and CY plus 2 important CY metabolites. The results indicate that aprepitant is well absorbed and does not auto-induce its metabolism. No significant drug interaction was observed with CY or its metabolites. A significant portion of the patients had subtherapeutic aprepitant concentrations; however, chemotherapy-induced nausea and vomiting were effectively managed. No dosage adjustment was necessary, and administration of aprepitant in HSCT at the prescribed dosage of 125 mg orally on day 1 and 80 mg orally on each consecutive day through day +4 after HSCT was well tolerated with no significant changes in CY pharmacokinetic parameters.",
keywords = "aprepitant, azole antifungals, cyclophosphamide, CYP450, Hematopoietic cell transplant, myeloablative regimen, pharmacokinetics, sinusoidal obstruction syndrome",
author = "Joseph Bubalo and Ganesh Cherala and McCune, {Jeannine S.} and Munar, {Myrna Y.} and Sunny Tse and Richard Maziarz",
year = "2012",
month = "4",
doi = "10.1177/0091270011398243",
language = "English (US)",
volume = "52",
pages = "586--594",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation

AU - Bubalo, Joseph

AU - Cherala, Ganesh

AU - McCune, Jeannine S.

AU - Munar, Myrna Y.

AU - Tse, Sunny

AU - Maziarz, Richard

PY - 2012/4

Y1 - 2012/4

N2 - Aprepitant, a neurokinin antagonist, is an effective antiemetic agent in chemotherapy for delayed nausea and vomiting. The study objective was to evaluate the pharmacokinetics of aprepitant and concurrent cyclophosphamide (CY), often a component of hematopoietic stem cell transplant (HSCT) conditioning regimen, in cancer patients undergoing HSCT. Forty subjects were randomized to either aprepitant or placebo in addition to standard antiemetics. Aprepitant or placebo was started 1 hour before the first chemotherapy or radiation dose for HSCT conditioning and administered daily until 4 days after infusion of the hematopoietic cell graft (for a total of 10-12 days). Serial blood samples were collected for aprepitant and CY plus 2 important CY metabolites. The results indicate that aprepitant is well absorbed and does not auto-induce its metabolism. No significant drug interaction was observed with CY or its metabolites. A significant portion of the patients had subtherapeutic aprepitant concentrations; however, chemotherapy-induced nausea and vomiting were effectively managed. No dosage adjustment was necessary, and administration of aprepitant in HSCT at the prescribed dosage of 125 mg orally on day 1 and 80 mg orally on each consecutive day through day +4 after HSCT was well tolerated with no significant changes in CY pharmacokinetic parameters.

AB - Aprepitant, a neurokinin antagonist, is an effective antiemetic agent in chemotherapy for delayed nausea and vomiting. The study objective was to evaluate the pharmacokinetics of aprepitant and concurrent cyclophosphamide (CY), often a component of hematopoietic stem cell transplant (HSCT) conditioning regimen, in cancer patients undergoing HSCT. Forty subjects were randomized to either aprepitant or placebo in addition to standard antiemetics. Aprepitant or placebo was started 1 hour before the first chemotherapy or radiation dose for HSCT conditioning and administered daily until 4 days after infusion of the hematopoietic cell graft (for a total of 10-12 days). Serial blood samples were collected for aprepitant and CY plus 2 important CY metabolites. The results indicate that aprepitant is well absorbed and does not auto-induce its metabolism. No significant drug interaction was observed with CY or its metabolites. A significant portion of the patients had subtherapeutic aprepitant concentrations; however, chemotherapy-induced nausea and vomiting were effectively managed. No dosage adjustment was necessary, and administration of aprepitant in HSCT at the prescribed dosage of 125 mg orally on day 1 and 80 mg orally on each consecutive day through day +4 after HSCT was well tolerated with no significant changes in CY pharmacokinetic parameters.

KW - aprepitant

KW - azole antifungals

KW - cyclophosphamide

KW - CYP450

KW - Hematopoietic cell transplant

KW - myeloablative regimen

KW - pharmacokinetics

KW - sinusoidal obstruction syndrome

UR - http://www.scopus.com/inward/record.url?scp=84859059106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859059106&partnerID=8YFLogxK

U2 - 10.1177/0091270011398243

DO - 10.1177/0091270011398243

M3 - Article

VL - 52

SP - 586

EP - 594

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 4

ER -